Industry leaders join together for historic Accelerating Cancer Cures Research Symposium

March 6th, 2012
Today, the Damon Runyon Cancer Research Foundation held its first Accelerating Cancer Cures Research Symposium, focused on rebuilding the ranks of physician-scientists specially trained to translate laboratory discoveries into new cancer therapies. The event, held at Pfizer Inc headquarters, brought together academic scientists and other leading pharmaceutical companies, including Eli Lilly and Company, Celgene, Genentech, Merck, and Millennium: The Takeda Oncology Company.

The symposium is the first of its kind since Damon Runyon, a New York-based foundation, launched its Accelerating Cancer Cures program in June 2011. Accelerating Cancer Cures is a five-year, multi-million dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for cancer patients. The initiative also eliminates barriers to progress by fostering communication and collaboration between academia and industry. It is supported by some of the world's leading companies and The Pharmaceutical Research and Manufacturers of America (PhRMA).

"We risk losing tremendous ground in our effort to find cures for cancer if we cannot attract new talent and new ideas to clinical research," said Damon Runyon Cancer Research Foundation President and CEO Lorraine Egan when the program launched. "Our best hope for crucial breakthroughs to prevent, diagnose and treat cancer lies with the committed young scientists who will be able to pursue critical translational research thanks to this effort."

Scientists from the nation's leading research institutions, including the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and the University of North Carolina, Chapel Hill, traveled to New York to attend.

Pfizer Vice President Jamey R. Skillings, MD, MSc, MBA, led a discussion on targeted therapies for cancer, and Celgene Vice President Rajesh Chopra, MD, PhD, chaired a session on immunotherapies. They were joined by twenty Damon Runyon-funded scientists.

The day ended with a panel discussion, moderated by Damon Runyon Chief Scientific Officer Yung S. Lie, PhD, about navigating the boundaries between industry and academia and overcoming barriers to collaboration and translational research.

More information:
www.damonrunyon.org/accelerate

Provided by Damon Runyon Cancer Research Foundation

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

ER docs are key to reducing health care costs

Emergency physicians are key decisionmakers for nearly half of all hospital admissions, highlighting a critical role they can play in reducing health care costs, according to a new report from the RAND Corporation.

Why we need to put the fish back into fisheries

Overfishing has reduced fish populations and biodiversity across much of the world's oceans. In response, fisheries are increasingly reliant on a handful of highly valuable shellfish. However, new research by the University ...

Lovelorn frogs bag closest crooner

What lures a lady frog to her lover? Good looks, the sound of his voice, the size of his pad or none of the above? After weighing up their options, female strawberry poison frogs (Oophaga pumilio) bag th ...

Blame your parents for bunion woes

A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot ...